ARWR - Arrowhead Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Arrowhead Pharmaceuticals, Inc.

225 South Lake Avenue
Suite 1050
Pasadena, CA 91101
United States
626-304-3400
http://arrowheadpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees116

Key Executives

NameTitlePayExercisedYear Born
Dr. Christopher R. AnzaloneCEO, Pres & Director1.62MN/A1969
Mr. Kenneth A. MyszkowskiChief Financial Officer577.02k1.2M1966
Dr. Bruce D. GivenChief Operating Officer908.06kN/A1954
Mr. Patrick O'BrienGen. Counsel602.5kN/A1964
Dr. Mark M. DavisFounder and Founder & Director of Insert Therapeutics Inc & CalandoN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Corporate Governance

Arrowhead Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 7. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 2; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.